Author

Longbin Liu

CHDI Foundation - Cited by 5,399

Biography

Longbin Liu is working in the Department of Cardiology of Shaoxing People’s Hospital in Shaoxing Hospital of Zhejiang University located in Shaoxing city, Zhejiang, China. Longbin has got international experience includes various programs, contributions and participation in different countries for diverse fields of study.
Title
Cited by
Year
KRAS G12C inhibitors and methods of using the same
JG Allen, JR Allen, AE Minatti, Q Xue, RP Wurz, CM Tegley, AJ Pickrell, ...US Patent 11,090,304, 2021202
32
2021
Kras g12c inhibitors and methods of using the same
BA Lanman, J Chen, AB Reed, VJ Cee, L Liu, DJ Kopecky, P Lopez, ...US Patent App. 17/031,607, 2021202
13
2021
In vitro and In vivo Assessment of Suitable Reference Region and Kinetic Modelling for the mGluR1 Radioligand [11C]ITDM in Mice
D Bertoglio, J Verhaeghe, Š Korat, A Miranda, L Wyffels, S Stroobants, ...Molecular Imaging and Biology 22, 854-863, 2020202
12
2020
Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates
F Herrmann, M Hessmann, S Schaertl, K Berg-Rosseburg, CJ Brown, ...Scientific Reports (1), 17977, 2021202
11
2021
Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s disease
D Bertoglio, J Bard, M Hessmann, L Liu, A Gärtner, S De Lombaerde, ...Science translational medicine 14 (630), eabm3682, 2022202
10
2022
Synaptic vesicle glycoprotein 2A is affected in the CNS of Huntington’s disease mice and post-mortem human HD brain
D Bertoglio, J Verhaeghe, A Miranda, S Stroobants, L Mrzljak, ...Journal of Nuclear Medicine, 2021202
10
2021
[11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins
L Liu, PD Johnson, ME Prime, V Khetarpal, MR Lee, CJ Brown, X Chen, ...Journal of Medicinal Chemistry 64 (16), 12003-12021, 2021202
10
2021
Synaptic vesicle glycoprotein 2A is affected in the central nervous system of mice with huntington disease and in the brain of a human with huntington disease postmortem
D Bertoglio, J Verhaeghe, L Wyffels, A Miranda, S Stroobants, L Mrzljak, ...Journal of Nuclear Medicine 3 (), 942-947, 2022202
6
2022
Validation, kinetic modeling, and test-retest reproducibility of [18F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice
D Bertoglio, F Zajicek, SD Lombaerde, A Miranda, S Stroobants, Y Wang, ...Journal of Cerebral Blood Flow & Metabolism 42 (10), 1867-1878, 2022202
5
2022
Longitudinal preclinical evaluation of the novel radioligand [11C] CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease
D Bertoglio, J Verhaeghe, A Miranda, L Wyffels, S Stroobants, L Mrzljak, ...European Journal of Nuclear Medicine and Molecular Imaging, 1-10, 2021202
5
2021
Kinetic Modelling and Test–Retest Reproducibility for the Dopamine D1R Radioligand [11C]SCH23390 in Healthy and Diseased Mice
D Bertoglio, J Verhaeghe, A Miranda, L Wyffels, S Stroobants, ...Molecular Imaging and Biology 23, 208-219, 2021202
4
2021
Design and Evaluation of [18F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates
L Liu, PD Johnson, ME Prime, V Khetarpal, CJ Brown, L Anzillotti, ...Journal of Medicinal Chemistry 66 (1), 641-656, 2022202
3
2022
Kras g12c inhibitors and methods of using the same
J Chen, NA Tamayo, L Liu, HL Wang, BA Lanman, RP Wurz, Y Shin, ...US Patent App. 17/482,20, 2022202
3
2022
A novel imaging ligand as a biomarker for mutant huntingtin-lowering in Huntington’s disease
D Bertoglio, J Bard, M Hessmann, L Liu, A Gärtner, SD Lombaerde, ...BioRxiv, 2021.07. 09.451725, 2021202
3
2021
Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification …
Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-0048566, designed for quantification …A Delva, M Koole, K Serdons, G Bormans, L Liu, J Bard, V Khetarpal, ...European Journal of Nuclear Medicine and Molecular Imaging 50 (1), 48-60, 0
2
2022
Substituted piperazines as KRAS G12C inhibitors
Substituted piperazines as KRAS G1C inhibitorsJG Allen, BA Lanman, J Chen, AB Reed, VJ Cee, L Liu, P Lopez, RP Wurz, ...US Patent 11,85,156, 0
2
2022
Altered Patterns of Neural Activity and Functional Connectivity Revealed by Dynamic rsfMRI in the Q175 Mouse Model of Huntington’s Disease
Altered Patterns of Neural Activity and Functional Connectivity Revealed by Dynamic rsfMRI in the Q75 Mouse Model of Huntington’s DiseaseT Vasilkovska, B Callewaert, S Salajeghe, D Pustina, L Liu, M Skinbjerg, ...Int. Soc. Magn. Reson. Med. Online Abstracts. Abstract, 20220
1
2021
Kras g12c inhibitors and methods of using the same
Kras g2c inhibitors and methods of using the sameJG Allen, BA Lanman, J Chen, AB Reed, VJ Cee, L Liu, P Lopez, RP Wurz, ...US Patent App. 7/579,359, 2022202
1
2022
The development of a structurally distinct series of BACE1 inhibitors via the (Z)-fluoro-olefin amide bioisosteric replacement
The development of a structurally distinct series of BACE inhibitors via the (Z)-fluoro-olefin amide bioisosteric replacementM Frohn, L Liu, AC Siegmund, W Qian, A Amegadzie, N Chen, H Tan, ...Bioorganic & Medicinal Chemistry Letters 30 (4), 27240, 2020202
1
2020

Referred From: https://scholar.google.com/citations?user=QYrqfb4AAAAJ&hl=en

Cited by
Citations 5399
h-index 37
i10-index 72
Open Access Journals